Byline: Dana-Farber Cancer Institute
BOSTON, July 16 (AScribe Newswire) -- Postmenopausal breast cancer patients with estrogen-sensitive tumors who undergo chemotherapy following surgery to increase their survival odds may not benefit from the regimen, which is often prescribed along with the hormone-blocking drug tamoxifen, according to an international study.
The research did show, however, that patients whose tumors were unresponsive to estrogen (known as ER-negative tumors) gained a decided benefit from chemotherapy. These patients were significantly less likely to relapse and less likely to die five years after treatment than those who didn't receive chemotherapy.
Published in the July 17 Journal of the National Cancer Institute, the findings question the value of the chemotherapy treatment following breast surgery in postmenopausal women who have relatively early tumors that haven't spread to their lymph nodes …
No comments:
Post a Comment